ESPE2024 Poster Category 2 Fat, Metabolism and Obesity (39 abstracts)
Single-center experience in using a once weekly Semaglutide injection in adolescents with obesity +/- Type 2 diabetes
Hajar Dauleh 1 , Rasha Amin 1 , Maheen Pasha 1 , Hoda Gad 2 , Tamara Elshareif 1 , Amel Khalifa 1 , Goran Petrovski 1 , Elwaseila Ahmed 1 , Ghassan Mohamadsalih 1 , Shiga Chirayath 1 , Khalid Albureshad 1 , Marwa Ibrahim 1 , Judith Campbell 1 , Manar Hamdan 1 , Douha Almajaly 1 , Fareeda Umer 1 , Aya Albahri 1 , Fatima Isamil 1 , Sara Saeed 1 , Hadeel almasarweh 1 , Erlinda cuatrona 1 , Roshirl Biglangawa 1 , Gina Inso 1 , Joanna Aler 1 , Ayah A. Eyalawwad 3 , Rayaz Malik 2 & Khalid Hussain 1
1Sidra Medicine, Doha, Qatar. 2Weill Cornell, Doha, Qatar. 3Hamad Medical Corporation, Doha, Qatar
Background: Childhood obesity presents a significant global health concern, leading to long-term morbidity and mortality. While lifestyle interventions remain fundamental, pharmacological approaches, particularly using glucagon-like peptide-1 (GLP-1) receptor agonists, show promise in certain patient populations. However, studies exploring this avenue, particularly in the Middle East and North African region, are limited. This study aims to share our experience with Semaglutide in managing obesity among children and adolescents, with or without diabetes, at Sidra Medicine.
Methodology: The study enrolled 56 obese participants, aged 8 to 19 years, with or without type II diabetes, from the endocrine clinics at Sidra Medicine between 2022 and 2024. Inclusion criteria included a BMI Z score of +2 and the absence of chronic diseases. Participants underwent personalized dietary interventions and 6-month treatment period with subcutaneous Semaglutide (starting dose 0.5 mg weekly for 4 weeks then titrated to 1 mg weekly for 6 months). Follow-ups scheduled at 3-month intervals. Primary outcome measures centered on alterations in weight and BMI relative to baseline. Biochemical markers were evaluated at baseline, 3 months, and 6 months to monitor HbA1c levels and detect potential adverse effects.
Results: Preliminary findings indicate that Semaglutide effectively induced weight loss in our patient cohort. From the initial 56 patients, data from 32 individuals are presented. Significant reductions in body weight and BMI were observed throughout the study. At baseline, average weight, weight SDS, BMI, and BMI SD were 108.3 kg, 2.7, 40.6 kg/m², and 2.5, respectively. By the 6-month mark, the average weight had decreased to 96.8 kg, with SDS, BMI, and BMI SD of 2.3, 38.3 kg/m², and 2.2, respectively (P < .001), indicating significant weight differences across the three-time points. Fourteen patients achieved a 5% reduction in body weight after 3 months of Semaglutide, with an additional 3 patients reaching this milestone at 6 months. On average, participants who completed 6 months of treatment lost approximately 10% of their original body weight. The treatment was generally well-tolerated, with gastrointestinal adverse events being the most commonly reported.
Conclusion: Our single-center experience suggests that Semaglutide holds promise as a pharmacological intervention for managing obesity in pediatric patients. Nevertheless, further prospective studies with larger sample sizes and longer follow-up periods are imperative to validate these findings and ascertain the optimal dosing, safety profile, and long-term efficacy of Semaglutide in this specific population.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more